New anti-Covid drug 'should work against various strains': DRDO Chairperson

The Defence Research and Development Organisation's (DRDO) new anti-COVID drug 2-DG should work against various strains of the COVID-19 virus, DRDO chairperson Dr G Satheesh Reddy said on Monday.

DRDO Covid drug
DRDO Covid drug
ANI General News
2 min read Last Updated : May 17 2021 | 5:38 PM IST

The Defence Research and Development Organisation's (DRDO) new anti-COVID drug 2-DG should work against various strains of the COVID-19 virus, DRDO chairperson Dr G Satheesh Reddy said on Monday.

"The drug 2DG developed by us should work against the various strains of the COVID-19 virus," Reddy told ANI when asked if the drug would be effective against the new strains and other mutated variants of the COVId-19 virus.

He added that the organisation was hoping to ramp up production of the drug up to one lakh sachet per day by the first week of June.

"From the first week of June, we are hoping to ramp up the production of the drug as the process to develop it takes around one month. We are hoping to increase the number of sachets production to one lakh per day," Reddy said.

The first batch of anti-COVID drug was released by Defence Minister Rajnath Singh and union health minister Harsh Vardhan on Monday.

Earlier, the Chairperson had informed that the first batch of anti-COVID drug would only be available only to AIIMS, Armed Forces Hospitals, DRDO hospitals and other places in need. It will be made available to other hospitals in June.

India on Monday reported 2,81,386 new COVID-19 cases, 3,78,741 discharges and 4,106 deaths in the last 24 hours, as per Union Health Ministry

The total cases in the country stands at 2,49,65,463, including 2,11,74,076 recoveries and 2,74,390 reported deaths. There are currently 35,16,997 active cases.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :DRDOCoronavirusCoronavirus Tests

First Published: May 17 2021 | 5:23 PM IST

Next Story